Evidence map›Paper›PMID 29338738›Full record

ArticleRetrovirology2018

Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient.

Jacqui Brener, Astrid Gall, Jacob Hurst, Rebecca Batorsky, Nora Lavandier, Fabian Chen, Anne Edwards, Chrissy Bolton, Reena Dsouza, Todd Allen and 4 more

Open access · goldAbstract readCase ReportsComparative Study
In one paragraph

Article in Retrovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Trends and Adaptive Optimal Set Points of CD4AIDS research and treatment · 2020
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Jacqui BrenerDepartment of Paediatrics, University of Oxford, Oxford, UK. jacquibrener@gmail.com.ORCID 0000-0002-6528-6471
Astrid GallDepartment of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Jacob HurstNuffield Department of Medicine, University of Oxford, Oxford, UK.
Rebecca BatorskyRagon Institute of MGH, MIT and Harvard, Boston, MA, USA.
Nora LavandierDepartment of Paediatrics, University of Oxford, Oxford, UK.
Fabian ChenDepartment of Sexual Health, Royal Berkshire Hospital, Reading, UK.
Anne EdwardsDepartment of GU Medicine, The Churchill Hospital, Oxford University NHS Foundation Trust, Oxford, UK.
Chrissy BoltonDepartment of Paediatrics, University of Oxford, Oxford, UK.
Reena DsouzaDepartment of Paediatrics, University of Oxford, Oxford, UK.
Todd AllenRagon Institute of MGH, MIT and Harvard, Boston, MA, USA.
Oliver G PybusDepartment of Zoology, University of Oxford, Oxford, UK.
Paul KellamWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Philippa C MatthewsNuffield Department of Medicine, University of Oxford, Oxford, UK.
Philip J R GoulderDepartment of Paediatrics, University of Oxford, Oxford, UK.
University of Oxford · GBRagon Institute of MGH, MIT and Harvard · USChurchill Hospital · GBRoyal Berkshire Hospital · GBUniversity of Cambridge · GBWellcome Sanger Institute · GB

Funding

Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan AfriR01AI046995 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2000 to 2014
$6.8M
Maximising Cure Potential in Paediatric HIV InfectionR01AI133673 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2017 to 2021
$1.4M
NIAID NIH HHS R01 AI046995NIAID NIH HHS R01 AI133673NIH HHS RO1AI46995Wellcome TrustWellcome Trust WT104748MA
6 · The paper itself

Abstract

backgroundThe factors determining differential HIV disease outcome among individuals expressing protective HLA alleles such as HLA-B*27:05 and HLA-B*57:01 remain unknown. We here analyse two HIV-infected subjects expressing both HLA-B*27:05 and HLA-B*57:01. One subject maintained low-to-undetectable viral loads for more than a decade of follow up. The other progressed to AIDS in < 3 years.

resultsThe rapid progressor was the recipient within a known transmission pair, enabling virus sequences to be tracked from transmission. Progression was associated with a 12% Gag sequence change and 26% Nef sequence change at the amino acid level within 2 years. Although next generation sequencing from early timepoints indicated that multiple CD8+ cytotoxic T lymphocyte (CTL) escape mutants were being selected prior to superinfection, < 4% of the amino acid changes arising from superinfection could be ascribed to CTL escape. Analysis of an HLA-B*27:05/B*57:01 non-progressor, in contrast, demonstrated minimal virus sequence diversification (1.1% Gag amino acid sequence change over 10 years), and dominant HIV-specific CTL responses previously shown to be effective in control of viraemia were maintained. Clonal sequencing demonstrated that escape variants were generated within the non-progressor, but in many cases were not selected. In the rapid progressor, progression occurred despite substantial reductions in viral replicative capacity (VRC), and non-progression in the elite controller despite relatively high VRC.

conclusionsThese data are consistent with previous studies demonstrating rapid progression in association with superinfection and that rapid disease progression can occur despite the relatively the low VRC that is typically observed in the setting of multiple CTL escape mutants.

Indexed as

Disease ProgressionAmino Acid SubstitutionCD4 Lymphocyte CountCD4-Positive T-LymphocytesCluster AnalysisEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency VirusGenetic VariationHigh-Throughput Nucleotide SequencingHIV-1HIV Core Protein p24HIV InfectionsHLA-B AntigensHumansMaleRNA, ViralEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency VirusHIV Core Protein p24HLA-B AntigensRNA, ViralCTL responseHIV-1HLASuperinfectionTransmission pairUltra-deep sequencing

Identifiers

PMID29338738
PMCPMC5771019
OpenAlexW2783743869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.